HealthcareServices

Phenylketonuria (PKU) Market Research: Growth Projections and Trends 2030

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the phenylketonuria (pku) market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Phenylketonuria (PKU) Market be in 2030 compared with 2026?

The phenylketonuria (PKU) market size has demonstrated significant growth in recent years. It is projected to expand from $0.93 billion in 2025 to $1.01 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.8%. The historical growth of the market is largely due to factors such as improved awareness of rare metabolic disorders, the expansion of newborn screening initiatives, the availability of dietary-based treatment options, increased diagnosis rates of PKU, and early clinical research into enzyme therapies.

The phenylketonuria (pku) market is anticipated to experience robust expansion over the coming years. Its valuation is projected to reach $1.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This anticipated growth throughout the forecast period stems from factors such as an expanding pipeline of gene therapies, a rise in the uptake of precision medicine strategies, increased capital directed towards rare disease research, the broadening availability of home-based management options, and an escalating need for therapies ensuring long-term disease control. Key trends foreseen during the forecast timeframe encompass a greater embrace of enzyme replacement therapies, an intensified concentration on the advancement of gene therapy, a surging requirement for customized dietary management solutions, the proliferation of newborn screening initiatives, and improved incorporation of digital tools for patient monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21257&type=smp

What Drivers Are Guiding Growth Patterns In The Phenylketonuria (PKU) Market?

The phenylketonuria (PKU) market is projected to see growth driven by an increase in genetic disorder occurrences. Genetic disorders are medical conditions arising from irregularities in an individual’s DNA, such as gene or chromosome mutations, deletions, or duplications. The uptick in genetic disorder cases can be attributed to several factors including an aging maternal population, environmental influences, advancements in diagnostic technologies, and heightened awareness, which collectively improve detection rates. Phenylketonuria provides insight into genetic disorders by demonstrating how inherited enzyme deficiencies can lead to severe metabolic complications. For instance, in March 2024, Gene People, a UK-based registered charity, reported that genetic conditions affect an estimated 1 in 25 children, impacting over 2.4 million children and adults in the UK. Additionally, around 30,000 newborns and children in the UK are diagnosed with a genetic condition each year. Therefore, the rising incidence of genetic disorders is a key factor propelling the phenylketonuria (PKU) market forward.

How Is The Phenylketonuria (PKU) Market Divided Into Segments?

The phenylketonuria (pku) market covered in this report is segmented –

1) By Type: Hyperphenylalaninemia, Mild Phenylketonuria (PKU), Moderate And Variant, Classic Phenylketonuria (PKU)

2) By Treatment Type: Enzyme Replacement Therapy, Gene Therapy, Medication, Dietary Therapy

3) By Diagnosis: Genetic Testing, Biochemical Testing, Newborn Screening

4) By End-User: Specialty Clinics, Research Institutes, Home Healthcare, Hospitals

Subsegments:

1) By Hyperphenylalaninemia: Mild Hyperphenylalaninemia, Moderate Hyperphenylalaninemia, Severe Hyperphenylalaninemia

2) By Mild Phenylketonuria (PKU): Mild PKU with dietary management, Mild PKU with enzyme supplementation

3) By Moderate And Variant: Moderate PKU with medication, Variant PKU with treatment variations

4) By Classic Phenylketonuria (PKU): Classic PKU with strict dietary management, Classic PKU with enzyme replacement therapy

Which Trends Are Influencing The Performance And Direction Of The Phenylketonuria (PKU) Market?

Leading companies in the phenylketonuria (PKU) market are prioritizing the development of innovative products, such as oral therapy, which aids in lowering blood phenylalanine (Phe) levels to prevent the toxic buildup causing complications in phenylketonuria (PKU). Oral therapy is a medical treatment administered by mouth, where the medicine is swallowed and absorbed via the digestive system. For instance, in July 2025, PTC Therapeutics, a US-based biopharmaceutical company, obtained Food and Drug Administration (FDA) approval for Sephience (sepiapterin), an oral therapy for children and adults with sepiapterin-responsive PKU/hyperphenylalaninemia. This treatment improves phenylalanine metabolism by increasing the activity of the deficient PAH enzyme through elevated tetrahydrobiopterin (BH4) levels, thereby helping to reduce blood phenylalanine concentrations. Additionally, Sephience is designed for use alongside a phenylalanine-restricted diet, offering a convenient and targeted option for the long-term management of PKU in responsive patients.

Which Leading Companies Dominate The Phenylketonuria (PKU) Market Share?

Major companies operating in the phenylketonuria (pku) market are Abbott Laboratories, Merck KGaA, Agios Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Nutricia International Private Limited, Codexis Inc., Eton Pharmaceuticals Inc., Vitaflo International Ltd., American Gene Technologies International Inc., Cambrooke Therapeutics Inc., Generation Bio Co., Mead Johnson & Company LLC, Synlogic Inc., Homology Medicines Inc., Aeglea BioTherapeutics Inc., MetaX Biosciences Ltd., SOM Biotech SL, Applied Molecular Transport Inc., Codexis Genomics, Bluebird Bio Inc., Alnylam Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/phenylketonuria-pku-global-market-report

How Does The Phenylketonuria (PKU) Market Perform Across Major Global Regions?

North America was the largest region in the phenylketonuria (PKU) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the phenylketonuria (pku) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Phenylketonuria (PKU) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21257&type=smp

Browse Through More Reports Similar to the Global Phenylketonuria (PKU) Market 2026, By The Business Research Company

Pharyngitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

Pheochromocytoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report

Paroxysmal Nocturnal Hemoglobinuria Pnh Market Report 2026

https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795